Brokers Set Expectations for SGMT Q2 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT) – Wedbush issued their Q2 2025 earnings per share estimates for Sagimet Biosciences in a research note issued on Monday, August 11th. Wedbush analyst Y. Zhong expects that the company will post earnings per share of ($0.56) for the quarter. Wedbush has a “Outperform” rating and a $28.00 price target on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.60) per share. Wedbush also issued estimates for Sagimet Biosciences’ Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.23) EPS, FY2026 earnings at ($2.34) EPS, FY2027 earnings at ($2.35) EPS, FY2028 earnings at ($2.19) EPS and FY2029 earnings at ($2.01) EPS.

A number of other brokerages have also weighed in on SGMT. Jones Trading boosted their target price on Sagimet Biosciences from $15.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, June 6th. Canaccord Genuity Group initiated coverage on Sagimet Biosciences in a research note on Thursday, July 24th. They set a “buy” rating and a $28.00 price target for the company. Finally, HC Wainwright upgraded Sagimet Biosciences to a “buy” rating and set a $29.00 price objective for the company in a research note on Thursday, August 7th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $26.57.

Sagimet Biosciences Price Performance

Shares of NASDAQ:SGMT opened at $8.67 on Thursday. Sagimet Biosciences has a 1-year low of $1.73 and a 1-year high of $11.41. The business has a fifty day moving average price of $8.59 and a 200-day moving average price of $5.24. The company has a market capitalization of $265.91 million, a PE ratio of -4.74 and a beta of 3.37.

Sagimet Biosciences (NASDAQ:SGMT) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.20.

Institutional Trading of Sagimet Biosciences

Several hedge funds have recently modified their holdings of the company. Jump Financial LLC purchased a new stake in shares of Sagimet Biosciences during the 2nd quarter worth approximately $1,130,000. XTX Topco Ltd raised its holdings in shares of Sagimet Biosciences by 137.0% during the 2nd quarter. XTX Topco Ltd now owns 25,624 shares of the company’s stock worth $195,000 after acquiring an additional 14,813 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Sagimet Biosciences by 8.9% during the 2nd quarter. American Century Companies Inc. now owns 42,285 shares of the company’s stock worth $322,000 after acquiring an additional 3,454 shares in the last quarter. Bailard Inc. purchased a new stake in Sagimet Biosciences during the 2nd quarter valued at $221,000. Finally, Geode Capital Management LLC raised its holdings in Sagimet Biosciences by 0.6% during the 2nd quarter. Geode Capital Management LLC now owns 265,324 shares of the company’s stock valued at $2,023,000 after buying an additional 1,600 shares during the period. 87.86% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, General Counsel Elizabeth Rozek sold 10,780 shares of the company’s stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $9.13, for a total transaction of $98,421.40. Following the sale, the general counsel directly owned 183,726 shares of the company’s stock, valued at $1,677,418.38. This represents a 5.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eduardo Bruno Martins sold 8,277 shares of the company’s stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $9.13, for a total value of $75,569.01. Following the sale, the insider directly owned 106,936 shares in the company, valued at $976,325.68. This trade represents a 7.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 84,535 shares of company stock valued at $771,805. Corporate insiders own 14.70% of the company’s stock.

Sagimet Biosciences Company Profile

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.